JP2010248203A5 - - Google Patents

Download PDF

Info

Publication number
JP2010248203A5
JP2010248203A5 JP2010126848A JP2010126848A JP2010248203A5 JP 2010248203 A5 JP2010248203 A5 JP 2010248203A5 JP 2010126848 A JP2010126848 A JP 2010126848A JP 2010126848 A JP2010126848 A JP 2010126848A JP 2010248203 A5 JP2010248203 A5 JP 2010248203A5
Authority
JP
Japan
Prior art keywords
lipoic acid
reagent
group
disease
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010126848A
Other languages
English (en)
Japanese (ja)
Other versions
JP5727721B2 (ja
JP2010248203A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010248203A publication Critical patent/JP2010248203A/ja
Publication of JP2010248203A5 publication Critical patent/JP2010248203A5/ja
Application granted granted Critical
Publication of JP5727721B2 publication Critical patent/JP5727721B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010126848A 1998-10-26 2010-06-02 リポ酸誘導体および疾患の治療におけるそれら誘導体の使用 Expired - Lifetime JP5727721B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10562898P 1998-10-26 1998-10-26
US60/105,628 1998-10-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000578304A Division JP4728481B2 (ja) 1998-10-26 1999-10-26 リポ酸誘導体および疾患の治療におけるそれら誘導体の使用

Publications (3)

Publication Number Publication Date
JP2010248203A JP2010248203A (ja) 2010-11-04
JP2010248203A5 true JP2010248203A5 (cg-RX-API-DMAC10.html) 2011-07-21
JP5727721B2 JP5727721B2 (ja) 2015-06-03

Family

ID=22306916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000578304A Expired - Lifetime JP4728481B2 (ja) 1998-10-26 1999-10-26 リポ酸誘導体および疾患の治療におけるそれら誘導体の使用
JP2010126848A Expired - Lifetime JP5727721B2 (ja) 1998-10-26 2010-06-02 リポ酸誘導体および疾患の治療におけるそれら誘導体の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000578304A Expired - Lifetime JP4728481B2 (ja) 1998-10-26 1999-10-26 リポ酸誘導体および疾患の治療におけるそれら誘導体の使用

Country Status (12)

Country Link
US (2) US6331559B1 (cg-RX-API-DMAC10.html)
EP (3) EP2145883A1 (cg-RX-API-DMAC10.html)
JP (2) JP4728481B2 (cg-RX-API-DMAC10.html)
AT (2) ATE451362T1 (cg-RX-API-DMAC10.html)
AU (1) AU774362B2 (cg-RX-API-DMAC10.html)
BR (1) BR9914789A (cg-RX-API-DMAC10.html)
CA (1) CA2348998C (cg-RX-API-DMAC10.html)
DE (2) DE69941800D1 (cg-RX-API-DMAC10.html)
ES (2) ES2229790T3 (cg-RX-API-DMAC10.html)
IL (2) IL142824A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA01004152A (cg-RX-API-DMAC10.html)
WO (1) WO2000024734A1 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2162586B1 (es) * 1999-11-25 2002-07-01 Moraleda Manuel Gomez Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
ATE328877T1 (de) 2000-11-30 2006-06-15 Basf Ag Verfahren zur herstellung von liponsäure und dihydroliponsaüre
DE60234164D1 (de) * 2001-03-19 2009-12-10 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
CN100367949C (zh) 2002-09-13 2008-02-13 有限会社绪方研究 黑色素消除制剂
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20040248982A1 (en) * 2003-06-09 2004-12-09 Dyer Gordon Wayne Use of compounds for the inhibition of proteins and UV protection
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US7129368B2 (en) * 2004-03-15 2006-10-31 Sonus Pharmaceuticals, Inc. Platinum carboxylate anticancer compounds
US7582418B2 (en) * 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
ES2442901T3 (es) * 2007-04-18 2014-02-14 Cornerstone Pharmaceuticals, Inc. Derivados de ácido lipoico
MX2009011165A (es) * 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
CN102089276A (zh) * 2008-03-04 2011-06-08 罗伯特·绍尔 酶结构、活性和/或表达水平的调节
AU2009251711B2 (en) 2008-04-01 2014-07-17 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
KR20110025168A (ko) * 2008-04-04 2011-03-09 로버트 쇼어 약학적 조성물
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
AU2009308152B2 (en) * 2008-10-21 2015-05-21 The General Hospital Corporation Cell transplantation
FR2937867B1 (fr) 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010062381A1 (en) * 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
WO2011046583A1 (en) * 2009-09-11 2011-04-21 Robert Shorr Pharmaceutical exploitation of oxidative stress in transformed cells
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668B1 (fr) * 2010-05-05 2012-07-13 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
JP6072684B2 (ja) 2010-08-06 2017-02-01 ザ ジェネラル ホスピタル コーポレーション ディー/ビー/エイ マサチューセッツ ジェネラル ホスピタル 細胞処置システムおよび細胞処置装置
BR112015014327A2 (pt) * 2012-12-19 2020-01-28 Cornerstone Pharmaceuticals Inc compostos farmacêuticos
US9605012B2 (en) 2013-01-17 2017-03-28 Garnett Mckeen Laboratory, Inc. Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases
EP3189033B1 (en) 2014-06-19 2020-08-05 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2747702T3 (es) 2014-06-19 2020-03-11 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用
CN117919421A (zh) * 2023-12-28 2024-04-26 石河子大学 转录因子klf7在制备抑制宫颈癌进展的药物中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362916C (de) 1921-08-13 1922-11-02 Eduard Duerr Abnehmbares Mikrometer fuer Schublehren
GB758897A (en) * 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2872458A (en) * 1954-12-30 1959-02-03 Merck & Co Inc Addition product of a metal hydrocarbon mercaptide with an alpha-halogamma-butyrolactone
JPS57123107A (en) 1981-01-26 1982-07-31 Pola Chem Ind Inc Cosmetic
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
DE3626116A1 (de) 1986-08-01 1988-02-11 Karl Thiel Thermostatische regeleinrichtung fuer heizungen bzw. heizaggregate
DE3629116A1 (de) * 1986-08-27 1988-03-10 Asta Pharma Ag Verfahren zur herstellung enantiomerenreiner r-(+)-(alpha)-liponsaeure und s-(-)-(alpha)-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
JPH03193758A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The 新規γ―アミノ酪酸誘導体
ATE162715T1 (de) * 1991-07-05 1998-02-15 Asta Medica Ag Verwendung von schwefel enthaltenden carbonsäuren zur bekämpfung von pathophysiologisch bedingten erregungsstörungen
DE4137773A1 (de) * 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
WO1994006794A1 (en) 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US5463093A (en) 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
DE19601787C1 (de) * 1996-01-19 1997-07-24 Asta Medica Ag Herstellung und Verwendung von Salzen der 6,8-Bis(amidiniumthio)-octansäure
ATE310738T1 (de) * 1996-07-05 2005-12-15 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH11124379A (ja) * 1997-10-17 1999-05-11 Ss Pharmaceut Co Ltd ジチオリリデンアセトアミド誘導体
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
ES2856125T3 (es) 2016-02-05 2021-09-27 Ea Pharma Co Ltd Derivado de sulfonamida y composición farmacéutica que contiene la misma

Similar Documents

Publication Publication Date Title
LoPachin et al. Molecular mechanisms of the conjugated α, β-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases
Duan et al. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor
Bouchain et al. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation
US9730902B2 (en) Polyamine transport inhibitors as novel therapeutics
CA2348998A1 (en) Lipoic acid derivatives and their use in treatment of disease
ES2759312T3 (es) Compuestos de aminocarbonilcarbamato
JP2015518055A5 (cg-RX-API-DMAC10.html)
JP2013507423A5 (cg-RX-API-DMAC10.html)
WO2010118706A2 (es) Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
JP2015512943A5 (cg-RX-API-DMAC10.html)
JP2009536191A5 (cg-RX-API-DMAC10.html)
JP2010536889A5 (cg-RX-API-DMAC10.html)
JP2014507470A5 (cg-RX-API-DMAC10.html)
JP2012533559A5 (cg-RX-API-DMAC10.html)
Heller et al. Synthesis and proapoptotic activity of oleanolic acid derived amides
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2010522710A5 (cg-RX-API-DMAC10.html)
JP2011046708A5 (cg-RX-API-DMAC10.html)
CY1113280T1 (el) Νεες απο του στοματος φαρμακοτεχνικες μορφες οsρεμιfενε
JP2013513607A5 (cg-RX-API-DMAC10.html)
NO20082181L (no) Formuleringer av Fispemifen
JP2019529501A5 (cg-RX-API-DMAC10.html)
JP2025163212A5 (cg-RX-API-DMAC10.html)
JP2012518648A5 (cg-RX-API-DMAC10.html)
US12492164B2 (en) Fluorine substituted cyclohexene analogues of gamma-aminobutyric acid (GABA)